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AbstrAct
Objectives We aim to evaluate the safety of performing 
percutaneous native kidney biopsy (PKB) as an outpatient 
procedure (implying an observation period of 6 hours) 
compared with the traditional inpatient policy.
Design, setting, participants and measurements Group 
I, in whom PKB was performed in the outpatient 
department (2012–2016) and followed by 6 hours’ 
observation period and then by regular outpatient visits 
and group II, in whom PKB was performed and followed 
by at least 1 day hospital admission. Group II included 
retrospectively retrieved patients who underwent PKB in 
our Institution between January 2000 and November 2012 
as an inpatient procedure. All biopsies were performed by 
a single nephrologist following a structured protocol.
Results 462 biopsies were reviewed, 210 (45.5%) of 
patients were women and the mean age was 54.7±17.9 
years. One hundred and twenty-nine (27.9%) of these 
biopsies were performed in outpatients. A total of 36 
(7.8%) of patients developed a complication, and of those, 
9 (1.9%) suffered for a major complication (arteriovenous 
fistula (six cases, 1.2%), ischaemic stroke (2; 0.4%), 
thromboembolic pulmonary embolism (1; 0.2%)) and 
27 (5.8%) for minor(macroscopic haematuria (12 cases, 
2.6%), haematomas on sonography not requiring 
intervention (15 cases, 3.2%)). When comparing the 
complication rate between groups I and II, no statical 
difference was observed. When analysing together both 
groups, after multivariate analysis, serum creatinine 
>3 mg/dL (OR 2.03, 95% CI 1.18 to 6.81) and known 
severe hypertension (OR 2.01, 95% CI 1.2 to 4.7) were 
found to be independent risk factors for minor and major 
complications, respectively. Conversely, we found no 
association of risk with the number of biopsy passes, 
gender, age, diagnosis, presence of haematuria before the 
kidney biopsy nor the degree of proteinuria.
Conclusions Outpatient biopsy could be a valuable, safe 
and perhaps cost-effective method of obtaining diagnostic 
renal tissue in the majority of patients.
IntroductIon
Percutaneous biopsy of native kidneys is an 
important diagnostic tool for clinicians seeking 
a diagnosis for patients with kidney disease. The 
primary risks for percutaneous native kidney 
biopsy (PKB) range from mild complica-
tions such as postprocedural pain and gross 
haematuria to major complications such as 
large haematomas requiring blood transfusion, 
uncontrolled bleeding requiring embolisation 
or surgical nephrectomy and rarely death.1 
The technique for obtaining tissue has evolved 
with the emergence of direct ultrasound guid-
ance as the standard of care, dramatically 
improving procedural safety and diagnostic 
yield.2 While a number of centres worldwide 
require overnight inpatient observation (IO) 
following PKB, several studies have suggested 
the safety of the outpatient ‘day surgery’ 
(ODS) approach.2 3 However, to date, debate 
still exists on the appropriate observation time 
after PKB. In fact, despite some studies showing 
that discharging patients within 4–6 hours after 
biopsy seems to be safe,4–6 Whittier and Korbet 
found that an observation period of less than 
8 hours following biopsy missed 33% of compli-
cations.7
We carried out a prospective observational 
study over a 5-year period of consecutive 
outpatient native renal biopsies to evaluate 
safety of ODS-PKB. Outcomes and the rate of 
complications after ODS-PKB were compared 
with IO-PKD performed in our Institution 
between January 2000 and November 2012. 
Besides, we aimed to identify preprocedure 
risk factors for complications (either minor 
or major) after a PKB.
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Research
Strengths and limitations of this study
 ► This is the largest reported cohort of percutaneous 
native kidney biopsies (PKB) performed in a single 
centre by a single experience nephrologist using 
automated devices and ultrasound guidance 
following a structured protocol.
 ► Our experience is not biased by heterogeneity in PKB 
approaches and level of expertise of the operator 
performing PKB.
 ► One limitation of our study is ambispective fashion 
of study design. Both prospective and retrospective 
data were studied.
 o
n
 13 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-015243 on 21 June 2017. Downloaded from 
2 Roccatello D, et al. BMJ Open 2017;7:e015243. doi:10.1136/bmjopen-2016-015243
Open Access 
MaterIals and Methods
Patients selection
For the purpose of this study, two groups of patients were 
considered: group I, in whom renal biopsy was performed 
in the outpatient department (2012–2016) and followed 
by 6 hours’ observation period and then by regular outpa-
tient visits and group II, in whom kidney biopsy was 
performed and followed by at least 1 day hospital admis-
sion.
Patients in group I were prospectively enrolled since 
January 2012, when we began performing renal biopsies 
as outpatient procedures in all consecutive patients using 
a standardised outpatient protocol (as provided in the 
supplementary material). A prospective computerised 
database was used to enter the data.
Group II included retrospectively retrieved patients 
who underwent PKB in our Institution between January 
2000 and November 2012 as inpatient procedure. Patients 
whose data set was not fully available were excluded from 
our analysis (three cases).
PKB were performed when needed as part of good 
clinical practise for patients refereed to our department. 
Data collection was performed according to the local 
legislation of the institutional review board.
Pre-ods-PKB standardised procedures
Patients are scheduled within 3 to 7 days from the day 
of call. Pre-ODS-PKD standardised procedures includes 
cell blood count (CBC), renal function panel, coagula-
tion profile (prothrombin time, partial thromboplastin, 
bleeding time, fibrinogen, PFA-100, platelet count) and 
ECG. Antiplatelets/anticoagulant therapies are screened 
and haematological evaluation is routinely requested in 
patients requiring therapy adjustment prior to biopsy.
real-time ultrasound-guided renal biopsy
All biopsies were performed by a single nephrologist 
(DR) with the guidance of an expert radiologist who 
also performed an ultrasound examination of the kidney 
prior to PKB. PKB is performed following a structured 
protocol. In brief, the skin is prepped with antiseptic 
solution and draped in the customary fashion. A sterile 
cover is placed over the ultrasound probe and the kidney 
visualised. The skin and subcutaneous tissue are anaesthe-
tised with lidocaine. The automated biopsy gun (needle 
18 gauge, 15 cm) was used. Under real-time ultrasound 
guidance, the biopsy needle gun is advanced. Once it is 
close to the renal capsule, the gun is fired with the patient 
holding his or her breath. The biopsy needle is retrieved, 
and the specimen placed in a media container and sent 
to surgical pathology. Three passes are performed per 
patient. As stated in the protocol, desmopressin acetate 
is routinely administered prior to PKB (0.4 microgr/Kg). 
Post-ods-PKB standardised monitoring
Patients are placed in a prone position on the bed for 
at least 2 hours. Patients received intravenous hydra-
tion and are observed for symptoms of urine retention. 
Monitor-urine analysis for microscopic or macroscopic 
haematuria is routinely performed. Half-hourly measure-
ments of pulse and blood pressure for 2 hours after PKD 
and then hourly until discharge are performed. Postbi-
opsy imaging was done in all the patients following the 
protocol. Additional imaging investigations, including 
additional sonography were performed when clinically 
indicated at the discretion of the attending physician. 
Minor or major complication definition
Postbiopsy bleeding complications were categorised as 
either minor or major. Minor complications included 
gross haematuria and/or subcapsular perinephric 
haematoma (<5 cm diameter) that spontaneously 
resolved without the need for further intervention. 
Major complications were defined as those that required 
an intervention for resolution, either the transfusion of 
blood products or an invasive procedure (angiography, 
surgery), and those that might potentially led to acute 
renal obstruction or failure, septicaemia or death.
Subcapsular haematoma >5 cm and/or those requiring 
intervention (despite the size) were considered major 
complications
The size of postbiopsy haematomas (surface area) was 
defined as the product of the longest and the shortest 
diameters on the two-dimensional sonographic pictures.
data analysis
The prospective database included demographic and 
clinical features, laboratory values, biopsy complications 
and diagnostic or therapeutic procedures to manage 
haemorrhagic complications. In addition, the surgical 
pathology reports were used to ascertain the adequacy 
of renal tissue and pathological diagnosis. Univariate 
analysis was performed to assess the association between 
complications and risk factors using the Pearson, χ2 and 
Fisher exact tests. For univariate analysis, the following 
variables were considered in the model: number of 
biopsy passes, gender, age, diagnosis, kidney size at 
sonographic investigations, presence of haematuria 
before the kidney biopsy, the degree of proteinuria, 
haemoglobin level before the kidney biopsy, thrombocy-
topenia, severe arterial hypertension, serum creatinine 
level before the kidney biopsy, the use of antiplatelets, 
low molecular weight heparin (LMWH) and antihyper-
tensive agents.
Multivariate logistic regression analysis was performed 
to identify significant independent factors adjusted for 
the potential confounding risk factors able to predict 
a complication; the results are expressed as OR with 
95% CI. The final multivariate logistic regression model 
includes the following variables: gender, age, diagnosis, 
the degree of proteinuria, haemoglobin level before the 
kidney biopsy, severe arterial hypertension, serum creati-
nine level before the kidney biopsy, the use of antiplatelet 
agents (as described in online Supplementary table 1s). 
The forward conditional techniques were used to find the 
final model.
 o
n
 13 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-015243 on 21 June 2017. Downloaded from 
 3Roccatello D, et al. BMJ Open 2017;7:e015243. doi:10.1136/bmjopen-2016-015243
Open Access
Table 1 Demographic, clinical and laboratory findings in groups I and II
2000–2015 2000–2012 (inpatients) 2012–2015 (outpatients) p Value
Biopsies 462 333 129
Passages, mean±SD/median (range) 2.6±0.7/3 (1–5) 2.9±0.6/3 (1–5) 3.1±0.6/3 (2–5) NS
Glomeruli, mean±SD/median (range) 19.9±11.3/18 (6–71) 21.6±12.4/20 (1–71) 23.9±12/23 (3–58) 0.01
Age, mean±SD 54.7±17.9 56±19 52±17.6 NS
Female, n (%) 180 (39) 114 (34) 66 (51) NS
Admission duration (days), mean±SD/
median (range)
– 1.1±0.6/1 (1–7) –
sCr (mg/dL), mean±SD/median (range) 1.67±1.2/1.3 (0.5–7) 1.56±0.9/1.3 (0.5–6) 1.8±1.24/1.4 (0.5–7) NS
sCr >3 (mg/dL), n (%) 124 (26.8) 89 (29.6) 35 (27.1) NS
Proteinuria (g/24 hours), mean±SD/
median (range)
2.6±2.3/2 (0.0–13) 2.7±2.2/2 (0.0–10) 2.6±2.2/2 (0.2–13) NS
Prebiopsy haematuria, n (%) 375 (81.2) 261 (78.4) 114 (88.4) 0.01
Resistant hypertension*, n (%) 110 (23.9) 93 (27.9) 17 (13.2) 0.008
Complications (any), n (%) 36 (7.8) 24 (7.2) 12 (9.3) NS
Minor, n (%) 27 (5.8) 19 (5.7) 8 (6.2) NS
Major, n (%) 9 (1.9) 5 (1.5) 4 (3.1) NS
*Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the 
management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J 
Hypertens 2013;31:1281–357.
In order to analyse risk factors associated with time 
to complication, multivariate survival analysis was 
performed using the proportional hazards model (Cox 
model) in the prospective arm of the study. Risk factors 
included sex, diagnosis (categorised in primary glomer-
ulopathy or systemic autoimmune condition), age ≥60, 
kidney size <8 cm at sonographic investigations, haema-
turia, nephrotic proteinuria, haemoglobin level (<10 g/
dL), thrombocytopenia, severe arterial hypertension, 
serum creatinine >3 mg/dL, use of antiplatelets, LMWH 
and antihypertensive agents.
results
A total of 462 biopsies (group I and group II) were 
included in this study, 210 (45.5%) of patients were 
women and the mean age was 54.7±17.9 years. Table 1 
summarised demographic, clinical and laboratory find-
ings in the whole cohort.
Twenty-three per cent of biopsies were performed for 
the diagnostic workup of nephrotic range proteinuria, 
16% for rapidly progressive renal insufficiency, 8% for 
acute kidney injury, 14% for a chronic kidney disease and 
the remaining 39% for non-nephrotic proteinuria and/
or haematuria.
A total of 36 (7.8%) of patients developed a compli-
cation, and of those, 9 (1.9%) suffered for a major 
complication (arteriovenous fistula (six cases, 1.2%), 
ischaemic stroke (2, 0.4%), thromboembolic pulmonary 
embolism (1, 0.2%)) and 27 (5.8%) for minor (macro-
scopic haematuria (12 cases, 2.6%), haematomas on 
sonography not requiring intervention (15 cases, 3.2%)).
Inpatients and outpatients
One hundred and twenty-nine (27.9%) of these biop-
sies were performed as outpatients and prospectively 
included. Data from 333 PKD performed as inpatients 
were retrospectively collected and analysed. Table 1 
summarised demographic, clinical and laboratory find-
ings, dividing patients in groups I and II.
Outpatients differed from inpatients with regard total 
glomeruli obtained (median=23 (1–71) vs median=20 
(3–58), p=0.01), prevalence of prebiopsy haematuria 
(78.4% vs 88.4%) and severe hypertension (13.2% vs 
27.9%). When comparing the complication rate between 
groups I and II, no statical difference were observed 
(overall, 24 (7.2%) complications in group I and 12 
(9.3%) in group II; 5 (1.5%) and 4 (3.1%) major, 19 
(5.5%) and 8 (6.2%) minor complications, respectively 
in groups I and II).
assessment of potential predictors of postbiopsy 
complications
When analysing together both groups, after multivariate 
analysis, serum creatinine >3 mg/dL (OR 2.03, 95% CI 
1.18 to 6.81) and known severe hypertension (OR 2.01, 
95% CI 1.2 to 4.7) were found to be independent risk 
factors for minor and major complications, respectively. 
Conversely, we found no association of risk with the 
number of biopsy passes, gender, age, diagnosis, kidney 
size at sonographic investigations, presence of haematuria 
before the kidney biopsy nor the degree of proteinuria. 
When focusing the survival prospective analysis only on 
group I, a similar trend was observed, but it failed to reach 
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a statistical significance. Online Supplementary table 1s 
summarises the factors associated with the presence of 
complication in the univariate and multivariate models 
(see online Supplementary file 2).
dIscussIon
The main finding in the present study is that a renal 
biopsy should be regarded as a safe procedure because 
it has a less than 2% overall rate of major complica-
tions. Importantly, when comparing the complication 
rate between groups I and II, no statical difference was 
observed, also when stratifying patients for major and 
minor complications (overall, 7.2% complication in 
group I and 9.3% in group II; 1.5% and 3.1% major, 5.5% 
and 6.2% minor complications, respectively, in groups I 
and II). Although the study was not randomised, it was 
performed prospectively with a proper follow-up of the 
patients.
These results are in line with Lin et al8 who found 
that there is no difference in the rate of complications 
between patients who are admitted and those observed for 
a 6-hour period, the latest being acceptable. By contrast, 
Whittier and Korbet7 found that 42% of complications 
following native kidney biopsy manifested at ≤4 hours, 
67% at ≤8 hours, 85% at ≤12 hours and 89% at ≤24 hours.
The main reason for overnight stay in the hospital is 
basically as a safety net in case there is a major compli-
cation.9 The major complication, which one could 
encounter, is severe bleeding causing a large retroperito-
neal haematoma. This complication can be catastrophic 
and should be addressed immediately by performing 
a selective renal arteriogram with embolisation of the 
bleeding arteriole, which will infarct a small portion of 
the kidney. This complication is in the order of 0% to 
6% depending on the authors2 7–17; the reasons for these 
differences are not cleared but may be related to the tech-
nique used (blind vs ultrasound-guided biopsy), operator 
experience, gauge of the biopsy needle and the number 
of passes. We demonstrated lower frequency of haemor-
rhagic complications with real-time ultrasound-guided 
biopsies, as compared with blind biopsies.10
Some authors believe that patients are still at risk 
for type complication beyond the 8-hour observation 
postbiopsy; we hypothesise that under a controlled 
environment (see standardised protocol) and a proper 
technique (real-time ultrasound), we can minimise this 
risk and be able to have the renal biopsy performed as an 
outpatient procedure. In detail, Marwah and Korbet9 in 
their study accounted together all complications (minor 
and major), and in their cohort, only 42% of the patients 
had the biopsy performed with an automated gun, the 
rest were performed with a manual biopsy device and 
all biopsies were performed with 14-gauge needles and 
there was no report on how many passes were performed. 
They timed the major complications, which accounted 
for 24 out of a total of 394 biopsies (6.6%) and reported 
that 19 of them were observed before the 8-hour mark. 
Thus, only five major complications were captured after 
8 hours of observation. Subsequently, when Whittier 
and Korbet7 re-evaluated the data and reported a series 
of 750 patients, in which they added the patients from 
the prior study, they concluded that less than 8 hours 
period of observation was not optimal and they reported 
that it could miss up to 33% of complications. Again, 
all complications (minor and major) were placed in 
the same category. Out of 750 biopsies, 45 had a major 
complication (6.6%). Thirty of them were diagnosed 
before 8 hours of observation, the other 15 were diag-
nosed between 9 and 24 hours. On the contrary, there 
are at least four studies showing different results. Fraser 
and Fairley reported only minor complications in a 
series of 118 patients (only two patients).4 Oviasu and 
Ugdodaga5 from Nigeria reported no complications in a 
series of 20 patients. Murphy and MacIsaac6 had similar 
data. Bairy et al reported on 178 outpatient renal biopsies 
and reported no major complications with only 13.2% of 
minor complications to include four patients with gross 
haematuria, 16 patients with small perinephric haema-
tomas and 3 with both haematuria and haematoma.3 No 
interventions were needed, and only two patients stayed 
overnight.
The current study shows similar results.
It is worth noting that we observed three throm-
botic events after PKD (two ischaemic strokes and one 
venous thromboembolism). As our protocol included 
the pre-PKD use of desmopressin, one could specu-
late a role of this agent in increasing the thrombotic 
risk. However, Manno et al18 when demonstrating in 
a double-blind randomised controlled clinical trial that 
prebiopsy desmopressin administration decreases the 
risk of bleeding and haematoma size in patients under-
going percutaneous kidney, they did not observe any 
episodes of thrombotic events in both desmopressin and 
control groups.
strengths and limitations
This is the largest reported cohort of biopsies performed 
in a single centre by a single experience nephrolo-
gist using automated devices and ultrasound guidance 
following a structured protocol. Despite that the single-
centre cohort design may potentially limit the external 
validity of our findings, our experience is not biased by 
heterogeneity in PKB approaches and the level of exper-
tise of the operator performing PKB.
One limitation of our study is ambispective fashion of 
study design. Both prospective and retrospective data 
were studied. These criteria were set a priori with the 
knowledge that cohort studies are prone to unpredictable 
bias and confounding by unknown factors and retrospec-
tive data analysis would only add to this risk. However, 
we used a multivariate analysis to ascertain the factors 
that contribute to postbiopsy complications, allowing for 
adjusting for potential known confounders, although 
unknown factors may not be accounted for.
 o
n
 13 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-015243 on 21 June 2017. Downloaded from 
 5Roccatello D, et al. BMJ Open 2017;7:e015243. doi:10.1136/bmjopen-2016-015243
Open Access
Finally, this study has also identified serum creat-
inine >3 mg/dL and known severe hypertension as 
significant independent predictors of complications; 
however, when comparing groups I and II, a similar 
trend was observed, but it failed to reach a statistical 
significance. This may be due to the small number of 
major complications, especially major, observed in this 
study, and whether or not these same parameters are also 
important predictors of the major episodes occurring 
in ODS-PKD patients requiring intervention which is 
uncertain.
In conclusion, our study provides further evidence that 
it is safe to perform PKB as outpatient procedure after 
careful screening for risk of bleeding, using an auto-
mated needle-gun system under an ultrasound guide, 
following a standardised protocol. Therefore, same-day 
discharge with a 6-hour observation period seems a 
medically adequate procedure, and this represents a 
significant finding, since outpatient biopsies are econom-
ically advantageous.
Contributors DR performed the kidney biopsies. DR and SS designed the study, 
collected the data and drafted the manuscript. DR, CN and MB participated in the 
clinical evaluation, patients selection and data collection and critically reviewed the 
manuscript. LS, EM and SB performed the laboratory investigations and critically 
reviewed the manuscript. SB participated in the data analysis.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The applied protocol for percutaneous kidney biopsies is 
attached and shared as supplementary material.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4.0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
references
 1. Parrish AE. Complications of percutaneous renal biopsy: a review of 
37 years' experience. Clin Nephrol 1992;38:135–41 http://www. ncbi. 
nlm. nih. gov/ pubmed/ 1395165
 2. Maya ID, Maddela P, Barker J, et al. Percutaneous renal biopsy: 
comparison of blind and real-time ultrasound-guided technique. 
Semin Dial 2007;20:355–8.
 3. Bairy M, Beleed K, Webb AT, et al. Safety of outpatient kidney 
biopsy: one center's experience with 178 native kidney biopsies. Am 
J Kidney Dis 2008;52:631–2.
 4. Fraser IR, Fairley KF. Renal biopsy as an outpatient procedure. Am 
J Kidney Dis 1995;25:876–8 http://www. ncbi. nlm. nih. gov/ pubmed/ 
7771483
 5. Oviasu E, Ugbodaga P. Evaluation of percutaneous renal biopsy 
as a day case procedure: experience from Nigeria. J Nephrol 
1998;11:246–8 http://www. ncbi. nlm. nih. gov/ pubmed/ 9831237
 6. Murphy BF, MacIsaac A. Percutaneous renal biopsy as a day-patient 
procedure. Am J Kidney Dis 1989;14:77 http://www. ncbi. nlm. nih. gov/ 
pubmed/ 2741939
 7. Whittier WL, Korbet SM. Timing of complications in percutaneous 
renal biopsy. J Am Soc Nephrol 2004;15:142–7.
 8. Lin WC, Yang Y, Wen YK, et al. Outpatient versus inpatient renal 
biopsy: a retrospective study. Clin Nephrol 2006;66:17–24 http://
www. ncbi. nlm. nih. gov/ pubmed/ 16878431
 9. Marwah DS, Korbet SM. Timing of complications in percutaneous 
renal biopsy: what is the optimal period of observation? Am J Kidney 
Dis 1996;28:47–52.
 10. Maya ID, Allon M. Percutaneous renal biopsy: outpatient observation 
without hospitalization is safe. Semin Dial 2009;22:458–61.
 11. Medawar W, Green A, Campbell E, et al. Clinical and histopathologic 
findings in adults with the nephrotic syndrome. Ir J Med Sci 
1990;159:137–40 http://www. ncbi. nlm. nih. gov/ pubmed/ 2397982
 12. Doyle AJ, Gregory MC, Terreros DA. Percutaneous native 
renal biopsy: comparison of a 1.2-mm spring-driven system 
with a traditional 2-mm hand-driven system. Am J Kidney Dis 
1994;23:498–503.
 13. Cozens NJ, Murchison JT, Allan PL, et al. Conventional 15 G needle 
technique for renal biopsy compared with ultrasound-guided spring-
loaded 18 G needle biopsy. Br J Radiol 1992;65:594–7. 1.
 14. Hergesell O, Felten H, Andrassy K, et al. Safety of ultrasound-
guided percutaneous renal biopsy-retrospective analysis of 1090 
consecutive cases. Nephrol Dial Transplant 1998;13:975–7.
 15. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. 
Autoimmun Rev 2011;11:6–13.
 16. Burstein DM, Korbet SM, Schwartz MM. The use of the automatic 
core biopsy system in percutaneous renal biopsies: a comparative 
study. Am J Kidney Dis 1993;22:545–52.
 17. Burstein DM, Schwartz MM, Korbet SM. Percutaneous renal biopsy 
with the use of real-time ultrasound. Am J Nephrol 1991;11:195–200 
http://www. ncbi. nlm. nih. gov/ pubmed/ 1962666
 18. Manno C, Bonifati C, Torres DD, et al. Desmopressin acetate in 
percutaneous ultrasound-guided kidney biopsy: a randomized 
controlled trial. Am J Kidney Dis 2011;57:850–5.
 o
n
 13 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-015243 on 21 June 2017. Downloaded from 
